Among five fatalities, there were two heart attacks, one case of infectious disease and one sudden death, as well as one case of suicide and two suicide attempts. Acomplia was approved in Europe in but since then its progress has been hit with a number of setbacks. A marketing application was pulled in the USA after it looked unlikely that approval would be granted because of potential psychiatric side effects and in Europe there have been reimbursement issues, so the UK decision represents something of a win for Sanofi.
Free news subscriptions Free RSS feeds. This compared to 4. Liraglutide is an injectable human glucagon-like peptide-1 GLP-1 analogue and its weight-lowering properties have been well-established in a number of trials.
The drug was approved for diabetes in Europe in July and is being marketed as Victoza, but the company is still waiting for the green light in the USA. The diabetes indication is comfortably the most important one for Novo at the moment but the weight loss market is a lucrative one. A number of drugs of failed such as Sanofi-Aventis' Acomplia rimonabant , which was pulled from the market over the risk of psychiatric adverse effects, including suicide and seizures, and Merck's taranabant.
Both of those treatments block cannabinoid type 1 receptors in the brain. Orlistat reduces weight by an average of 3 kilograms, whereas sibutramine and rimonabant each reduce weight by 4 kg to 5 kg, on average, Dr.
Raj S. Padwal and Dr. Sumit R.
0コメント